News Sentiment

ACRV sentiment intelligence

Acrivon Therapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.96 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend inactive

+14.0% over one week, +32.4% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction 14.0% Price confirming higher
Trend fit Trend inactive 32.4% over four weeks
Fair value -58.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 38
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
Market source 8
TradingView 6
simplywall.st 4
Quiver Quantitative 4
Finviz 3
Seeking Alpha 2
The Globe and Mail 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 19
Analyst action 5
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 60
Pluang Direct company coverage

Acrivon Therapeutics trades below cash value despite promising cancer therapy data and upcoming clinical milestones.

Acrivon Therapeutics (ACRV) is trading below its cash value despite promising early clinical data from its AP3 platform, which includes a 50% response rate in serous endometrial cancer with drug ACR-368. Upcoming catalysts are Phase 2b data for ACR-368 and Phase 1 expansion resul

Tone
Positive 76/100
Event
Balance sheet
Published
13 Jul 2026 13:41
Source
Pluang
Finviz Direct company coverage

ACRV - Acrivon Therapeutics Inc Options

This article provides a detailed financial overview of Acrivon Therapeutics Inc (ACRV) as of July 2, 2026. It includes key financial metrics such as market cap, income, sales, EPS, various ratios, stock performance, and insider/institutional ownership. The data is presented to of

Tone
Neutral 50/100
Event
Earnings
Published
03 Jul 2026 10:10
Source
Finviz
Finviz Direct company coverage

ACRV - Acrivon Therapeutics Inc Earnings

This article provides a detailed financial overview of Acrivon Therapeutics Inc (ACRV), including its last closing price, market capitalization, enterprise value, income, and sales figures. It also lists various financial ratios, EPS estimates, insider and institutional ownership

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 06:10
Source
Finviz
TradingView Direct company coverage

Enterprise value to EBITDA forward of Acrivon Therapeutics, Inc. – NASDAQ:ACRV

This article provides financial information for Acrivon Therapeutics, Inc. (NASDAQ: ACRV), specifically focusing on its enterprise value to EBITDA forward. It indicates that this data is part of a larger financial overview available on TradingView, which includes market data, new

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 00:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Acrivon Therapeutics, Inc. – NASDAQ:ACRV

This article displays the "Price to sales forward" financial metric for Acrivon Therapeutics, Inc. (NASDAQ: ACRV) on TradingView. It indicates that the market was closed with no trades at the time of viewing. The data is provided by ICE Data Services and FactSet.

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 03:39
Source
TradingView
TradingView Direct company coverage

Acrivon Therapeutics, Inc. Actuals & Estimates (NASDAQ:ACRV)

This article provides an overview of Acrivon Therapeutics, Inc. (NASDAQ: ACRV) stock, including its current price, market capitalization, and analyst estimates. It also covers financial actuals and estimates, stock performance, and key dates such as the next earnings report. The

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 06:10
Source
TradingView
Stock Titan Direct company coverage

Director-linked RA Capital funds receive 20,275 Acrivon (ACRV) stock options at $1.52

Entities affiliated with RA Capital, linked to director Dr. Derek DiRocco, have been granted 20,275 stock options in Acrivon Therapeutics (ACRV) at an exercise price of $1.52 per share, expiring in 2036. This is a routine, compensation-related grant, not an open-market trade, des

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 13:41
Source
Stock Titan
Stock Titan Direct company coverage

Acrivon (NASDAQ: ACRV) director granted 20,275 stock options at $1.52

Acrivon Therapeutics director Michael John Tomsicek was granted 20,275 stock options with an exercise price of $1.52 per share, expiring on June 16, 2036. These compensation-related options will vest on the day before the company's next annual meeting, contingent on his continuou

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 18:10
Source
Stock Titan
Stock Titan Direct company coverage

Acrivon Therapeutics (ACRV) director awarded 20,275-share option for RA Capital funds

Acrivon Therapeutics director Derek DiRocco was granted a stock option for 20,275 shares of common stock at an exercise price of $1.52, expiring on June 16, 2036. This option is held for RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P., with DiRocco disclaiming

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 17:39
Source
Stock Titan
Stock Titan Direct company coverage

Acrivon Therapeutics (ACRV) director Sharon Shacham awarded 20,275 stock options

Acrivon Therapeutics director Sharon Shacham was granted 20,275 stock options with an exercise price of $1.52 per share, expiring on June 16, 2036. The options will vest on the date immediately preceding Acrivon's next annual meeting of stockholders, provided Shacham continues he

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 20:42
Source
Stock Titan
Investing.com South Africa Direct company coverage

Form 4 Acrivon Therapeutics Inc For: 22 June By Investing.com

Investing.com reported on a Form 4 filing for Acrivon Therapeutics Inc. related to June 22. The article provides the company's stock symbol (ACRV) and a general market update, but no specific details from the Form 4 filing are included in the content.

Tone
Positive 59/100
Event
Market update
Published
22 Jun 2026 20:10
Source
Investing.com South Africa
Stock Titan Direct company coverage

Acrivon Therapeutics (ACRV) director receives 20,275 stock options at $1.52 strike

Acrivon Therapeutics (ACRV) director Palani Santhosh received a grant of 20,275 stock options with an exercise price of $1.52 per share and an expiration date of June 16, 2036. The options will vest on the date immediately preceding the company's next annual meeting of stockholde

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 19:42
Source
Stock Titan
Stock Titan Direct company coverage

Acrivon Therapeutics (ACRV) director receives 20,275 stock options at $1.52

Acrivon Therapeutics director Charles M. Baum received a grant of 20,275 stock options with an exercise price of $1.52 per share, expiring on June 16, 2036. The options will vest immediately before the company's next annual stockholder meeting, contingent on his continuous servic

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 19:42
Source
Stock Titan
Stock Titan Direct company coverage

Acrivon Therapeutics (ACRV) director granted options on 20,275 shares

Acrivon Therapeutics director Ivana Magovcevic-Liebisch was granted options to acquire 20,275 shares of the company's common stock at an exercise price of $1.52 per share. This grant is a compensation-related award, not an open-market purchase, and the options will vest on the da

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 19:42
Source
Stock Titan
The Globe and Mail Direct company coverage

Acrivon Shareholders Approve Expanded Equity Plan and Directors

Acrivon Therapeutics, Inc. shareholders approved an expanded equity incentive plan, increasing the share pool to 8,606,723 shares, and elected Michael Tomsicek and Charles Baum as Class I directors. This decision, with a 73.21% quorum, signals strong shareholder support for the c

Tone
Positive 65/100
Event
Market update
Published
19 Jun 2026 04:09
Source
The Globe and Mail
Investing.com Nigeria Direct company coverage

Acrivon Therapeutics shareholders approve equity plan changes and director elections

Acrivon Therapeutics shareholders have approved amendments to the company's 2022 Equity Incentive Plan, increasing the shares available for equity awards by 3,000,000 to a total of 8,606,723. Additionally, Michael Tomsicek and Charles Baum were elected as Class I directors, and P

Tone
Positive 71/100
Event
Market update
Published
18 Jun 2026 16:10
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Acrivon Therapeutics (ACRV) shareholders approve larger equity plan and elect directors

Acrivon Therapeutics, Inc. (ACRV) shareholders approved an Amended and Restated 2022 Equity Incentive Plan, expanding the number of shares authorized for equity awards to 8,606,723, including an additional 3,000,000 shares. The plan also features an annual automatic share reserve

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 02:40
Source
Stock Titan
TradingView Direct company coverage

Acrivon amends equity plan, shareholders approve 3,000,000-share increase

Acrivon Therapeutics, Inc. (ACRV) has approved an amended and restated 2022 Equity Incentive Plan. This includes a 3,000,000-share increase to the reserve and an automatic annual share-reserve adjustment through 2032. The plan aims to secure and retain services, provide incentive

Tone
Positive 67/100
Event
Market update
Published
17 Jun 2026 21:40
Source
TradingView
TradingKey Direct company coverage

Acrivon Therapeutics Inc (ACRV) Institutional Confidence

This article provides details on the institutional confidence in Acrivon Therapeutics Inc (ACRV) as of a recent update. It lists key institutional shareholders, the number of shares they hold, and the percentage change in their holdings. The data indicates the level of institutio

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 17:40
Source
TradingKey
Finviz Direct company coverage

ACRV - Acrivon Therapeutics Inc Stock Price and Quote

This page provides a comprehensive overview of Acrivon Therapeutics Inc (ACRV) stock, including its latest trading price, key financial metrics, performance indicators, and recent news and analyst ratings. It details the company's financial health, insider transactions, and upcom

Tone
Positive 63/100
Event
Analyst action
Published
08 Jun 2026 11:39
Source
Finviz
Market source Direct company coverage

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Acrivon Therapeutics announced an inducement grant to a new employee under Nasdaq Listing Rule 5635(c)(4). The grant, comprising options to purchase 111,150 shares of common stock, was made on May 15, 2026, with an exercise price based on the closing price that day. The options w

Tone
Neutral 50/100
Event
Market update
Published
06 Jun 2026 10:40
Source
Market source